luxafimloc   Click here for help

GtoPdb Ligand ID: 14692

Synonyms: GSK3882347
Compound class: Synthetic organic
Comment: Luxafimloc (also known as GSK3882347) is an orally bioavailable, mannose-containing small molecule with promising anti-virulence activity against uropathogenic Gram-negative bacteria. The chemical structure is claimed in GSK patent WO2020012336A1 [1] and was presented during the ACS Fall 2026 meeting's First Time Disclosures session [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 5
Rotatable bonds 4
Topological polar surface area 110.38
Molecular weight 396.38
XLogP 0.56
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC(=CC=C1[C@H]([C@@H]2[C@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)O)C3=CC(=CC(=C3)F)F
Isomeric SMILES FC=1C=C(C=C(C1)F)C2=CC(=C(C=C2)[C@H]([C@@H]3[C@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)O)C
InChI InChI=1S/C20H22F2O6/c1-9-4-10(11-5-12(21)7-13(22)6-11)2-3-14(9)16(24)20-19(27)18(26)17(25)15(8-23)28-20/h2-7,15-20,23-27H,8H2,1H3/t15-,16-,17-,18+,19+,20-/m1/s1
InChI Key MDGCFZRSOKMPFJ-QONVVCGCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Luxafimloc is in clinical development as an oral treatment for uncomplicated urinary tract infections (uUTIs). Three separate Phase 1 studies have been completed, evaluating safety, tolerability, and pharmacokinetics in healthy volunteers (NCT04488770); potential drug-drug interactions (NCT05760261); and microbiological response in female participants with uUTIs (NCT05138822). Results from these studies have not been published in peer reviewed literature (September 2026).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05760261 Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years Phase 1 Interventional GlaxoSmithKline
NCT05138822 Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections Phase 1 Interventional GlaxoSmithKline
NCT04488770 Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants. Phase 1 Interventional GlaxoSmithKline